(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.34%) $82.73
(6.55%) $2.05
(0.01%) $2 347.50
(-0.35%) $27.44
(4.08%) $959.75
(-0.23%) $0.933
(-0.38%) $10.98
(-0.52%) $0.796
(1.55%) $93.30
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.01%
-0.16% $ 70.46
@ $73.34
Ausgestellt: 14 Feb 2024 @ 16:26
Rendite: -3.93%
Vorheriges Signal: Feb 13 - 15:30
Vorheriges Signal:
Rendite: -1.89 %
Live Chart Being Loaded With Signals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...
Stats | |
---|---|
Tagesvolumen | 194 127 |
Durchschnittsvolumen | 174 795 |
Marktkapitalisierung | 1.27B |
EPS | $0 ( 2024-02-27 ) |
Nächstes Ertragsdatum | ( $1.130 ) 2024-05-02 |
Last Dividend | $0.456 ( 2010-07-02 ) |
Next Dividend | $0 ( N/A ) |
P/E | 23.25 |
ATR14 | $0.111 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-24 | Kozarich John W | Buy | 2 893 | Common Stock |
2024-04-24 | Kozarich John W | Sell | 2 893 | Non-Qualified Stock Option (right to buy) |
2024-03-25 | Davis Todd C | Buy | 3 556 | Common Stock |
2024-03-25 | Davis Todd C | Buy | 2 156 | Common Stock |
2024-03-25 | Davis Todd C | Buy | 2 855 | Common Stock |
INSIDER POWER |
---|
76.79 |
Last 99 transactions |
Buy: 847 979 | Sell: 102 779 |
Volumen Korrelation
Ligand Pharmaceuticals Korrelation
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Ligand Pharmaceuticals Korrelation - Währung/Rohstoff
Ligand Pharmaceuticals Finanzdaten
Annual | 2023 |
Umsatz: | $131.31M |
Bruttogewinn: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2023 |
Umsatz: | $131.31M |
Bruttogewinn: | $119.75M (91.20 %) |
EPS: | $3.02 |
FY | 2022 |
Umsatz: | $196.25M |
Bruttogewinn: | $143.42M (73.08 %) |
EPS: | $-0.310 |
FY | 2021 |
Umsatz: | $277.13M |
Bruttogewinn: | $214.96M (77.56 %) |
EPS: | $2.22 |
Financial Reports:
No articles found.
Ligand Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $9.36 | 2007-04-03 |
Last Dividend | $0.456 | 2010-07-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $9.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.65 | -- |
Div. Sustainability Score | 8.02 | |
Div.Growth Potential Score | 1.515 | |
Div. Directional Score | 4.77 | -- |
Year | Amount | Yield |
---|---|---|
2007 | $9.36 | 14.30% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0.456 | 3.50% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.378 | 1.500 | 2.44 | 3.66 | [0 - 0.5] |
returnOnAssetsTTM | 0.0596 | 1.200 | 8.01 | 9.62 | [0 - 0.3] |
returnOnEquityTTM | 0.0742 | 1.500 | -0.287 | -0.431 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 14.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 12.49 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.368 | 1.500 | 3.51 | 5.27 | [0.2 - 2] |
debtRatioTTM | 0.00740 | -1.500 | 9.88 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 2.60 | 1.000 | -0.148 | -0.148 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.84 | 2.00 | 9.05 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.245 | 2.00 | -0.122 | -0.245 | [0 - 20] |
debtEquityRatioTTM | 0.00880 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.920 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0666 | 1.000 | -0.669 | -0.669 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.158 | 0.800 | -2.28 | -1.826 | [0.5 - 2] |
Total Score | 8.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.83 | 1.000 | 7.59 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0742 | 2.50 | -0.185 | -0.431 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.245 | 2.00 | -0.0815 | -0.245 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.84 | 2.00 | 9.05 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0118 | 1.500 | -3.25 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.378 | 1.000 | 3.06 | 0 | [0.1 - 0.5] |
Total Score | 1.515 |
Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.